Future policy for future precision medicine
| Reference number | |
| Coordinator | RISE Research Institutes of Sweden AB - RISE AB - Digitala System |
| Funding from Vinnova | SEK 999 709 |
| Project duration | April 2025 - April 2026 |
| Status | Ongoing |
| Venture | Regulation and cutting-edge technology |
| Call | Rules and instruments for cutting-edge technology |
Purpose and goal
Synthetic biology, multi-omics and AI are redefining precision medicine, enabling personalized treatment of chronic diseases. But for these technologies to deliver real impact, new rules and governance models are needed. This project explores how policy can be adapted to ensure the safe, fair and effective implementation of these technologies in IBD care—and pave the way for the precision medicine of tomorrow.
Expected effects and result
The project will result in concrete policy recommendations for the safe and fair implementation of synthetic biology and multi-omics in IBD treatment. Findings will be disseminated through a research report, seminars, and dialogue with healthcare providers and policymakers, aiming to build trust in new technologies and foster long-term conditions for healthcare innovation.
Planned approach and implementation
The project will be carried out as a policy lab using the double diamond of service design, involving needs analysis, solution development and testing. Four work packages cover project management, mapping, regulatory testing, and dissemination. An iterative process with workshops and stakeholder reviews ensures the results are anchored in real healthcare needs.